| Editor's Note: Last day to VOTE in #FierceMadness: The Best Biotech Name Tournament Elite 8. Get your votes in now! |
Today’s Big NewsApr 2, 2024 |
| By Gabrielle Masson More than 60 years after RhoGAM’s approval, Johnson & Johnson's Katie Abouzahr, M.D., is hoping to build off the pharma’s own legacy and bring another maternal fetal immunology treatment to market. |
|
|
|
By Max Bayer Verve has halted enrollment in a phase 1 study testing its lead asset after a patient experienced two sets of grade 3 side effects. The focus now is on a second PCSK9 base editor, VERVE-102. |
By Nick Paul Taylor Gritstone bio’s gamble on a novel endpoint has backfired. The cancer vaccine failed to trigger hoped-for changes in circulating tumor DNA, causing the phase 2 trial to miss its primary endpoint and leaving the biotech clinging to immature survival data. |
By Max Bayer Roivant's brepocitinib is back in the driver's seat with new phase 2 NIU data that the company is touting as some of the best seen in the indication. The asset is rebounding from a midstage lupus failure at the end of 2023. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
By Annalee Armstrong Ginkgo Bioworks’ swift moving business development team is slowing down long enough to load up some new chimeric antigen receptor (CAR) assets from Modulus Therapeutics. |
By James Waldron Ipsen has become the newest entrant in the antibody-drug conjugate race, handing over around $90 million in near-term payments to Sutro Biopharma in return for the global rights to a preclinical candidate. |
By Gabrielle Masson Carisma Therapeutics plans to let go of 37% of staffers and drop one of two clinical assets in an effort to fuel the immunotherapy-focused biotech into the third quarter of 2025. |
By Helen Floersh Ring Therapeutics’ hunt for new human viruses that can deliver gene therapies multiple times in a single patient appears to have landed on a viable candidate, new mouse data have suggested. |
By Helen Floersh A low dose of a DNMT inhibitor with EZH2 inhibitors induced changes in cancer cells that would make them more vulnerable to the immune system. A new clinical trial will evaluate the finding in patients. |
By Conor Hale Developed in collaboration with the Mayo Clinic, the software can detect a key indicator of heart performance through Eko's digitally enhanced stethoscopes. |
By Angus Liu Lonza’s search for a CEO has led the Swiss CDMO giant to its compatriot competitor, Siegfried. The appointment of Wolfgang Wienand could end a period of leadership instability marked by multiple CEO handovers since 2019. |
By Angus Liu After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market. |
By Noah Tong Cityblock Health and Molina Healthcare are joining forces to provide better care to dually eligible members. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now. 
|
|
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
